Navigation Links
Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
Date:11/11/2008

HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead product, varespladib (A-002) at the American Heart Association (AHA) Annual Conference in New Orleans, Louisiana. Anthera has completed two Phase II trials in varespladib for the treatment of coronary heart disease. At the AHA conference, Anthera and its collaborators released new data from the Phase II PLASMA-2 study, which examined varespladib (A-002) in patients with cardiovascular disease.

Results from the most recent study showed that in patients with coronary heart disease (CHD) currently on statin therapy:

-- Varespladib had a significant anti-inflammatory effect as measured by a greater than 20% relative reduction in C-reactive protein

-- Varespladib had a substantial reduction in the target enzyme and pro- inflammatory marker, secretory phospholipase A2 (84%, p<.0001)

-- Varespladib resulted in a significant reduction in LDL in CHD patients (15%, p=.0006)

-- Varespladib caused a significant reduction in small LDL particles in CHD patients

-- Varespladib established a once a day dosing schedule with a clearly defined dose response

-- Varespladib continued to have a strong safety profile, confirming results from previous studies

"We are pleased to confirm the anti-inflammatory effect and safety profile of varespladib in patients with CHD," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with an opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"Along with the Phase II PLASMA data presented at the American College of Cardiology earlier this year, today's data at AHA confirms our confidence in varespladib and its potential as new therapeutic to treat cardiovascular disease," said Dr. Colin Hislop, M.D., Senior Vice President of Cardiovascular Products at Anthera Pharmaceuticals, Inc. "We look forward to data from the on-going FRANCIS trial to provide us with additional information on varespladib in the setting of an acute coronary event, specifically the impact of varespladib on markers of inflammation that may play a critical role in this disease."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge

(650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Presents Data on Varespladib at ATVB Meeting
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
4. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
5. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
8. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
9. Job-related stress: NIST demonstrates fatigue effects in silicon
10. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... 12th annual Inventors Recognition Reception at Purdue Research Park of West ... member in recognition of outstanding contributions to, and success with, commercializing discoveries from ...
(Date:2/23/2017)... 2017 Aviva Systems Biology Corporation (ASB) ... of GenWay Biotech Incorporated, a protein solutions and ... offering for both the research and diagnostic markets. ... enhance capabilities for both entities. GenWay,s 18 years of ... nicely complement ASB,s objective to become a leading ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology ... for research and clinical applications. The terms of the transaction were not disclosed. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... provider of women’s health, primary care, and specialty education, announced today it ... Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and is ...
Breaking Biology Technology:
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):